EP300 and colorectal cancer: Several reports have demonstrated p300 overexpression in other cancers, including skin, liver, esophageal, nasopharyngeal, lung, breast, prostate and colorectal cancers, and have described the poorer prognoses of patients with tumors with higher p300 expression level than of patients with tumors that express less p300 [9–16].